Opendata, web and dolomites


Distinctive characterization of regulatory plasma cells and pro-inflammatory B cells in immunity: their origins, molecular properties, and cellular fates.

Total Cost €


EC-Contrib. €






 PREG-LAB project word cloud

Explore the words cloud of the PREG-LAB project. It provides you a very rough idea of what is the project "PREG-LAB" about.

functions    patients    regulators    depletion    opposite    autoimmune    complete    antibody    suppress    track    mediated    inhibited    arthritis    sparing    cell    model    guide    phenotypes    autoantibody    precedes    beneficial    indicating    eae    candidate    animal    primary    inhibitory    rituximab    effect    cells    ed    drivers    35    cytokines    agents    vivo    symptoms    compartment    multiple    characterizing    urgent    immune    improvement    immunity    paradoxical    largely    individuals    remaining    secretion    mechanism    deleterious    instance    distinctively    pro    clinical    highlighted    exacerbation    markers    infectious    severe    diseases    molecular    lack    experimental    subsequently    inflammatory    healthy    encephalomyelitis    sclerosis    few    pathologies    human    play    chronic    recovery    ms    drove    levels    mice    genetic    rheumatoid    pathogenesis    models    roles    identification    onset    interleukin    characterization    similarly    conversely    act    negative    independent    anti    cytokine    il    expressing    single    disease    producing    therapy    depleting   

Project "PREG-LAB" data sheet

The following table provides information about the project.


Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙999˙375 €
 EC max contribution 1˙999˙375 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-CoG
 Funding Scheme ERC-COG
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
2    Deutsches Rheuma-Forschungszentrum Berlin DE (Berlin) participant 81˙250.00


 Project objective

B cells can act both as negative regulators and as drivers of immunity through the production of cytokines. Through secretion of interleukin (IL)-10 B cells inhibited immunity in autoimmune and infectious diseases. For instance, IL-10 from B cells drove complete recovery from disease in experimental autoimmune encephalomyelitis (EAE), the primary animal model for multiple sclerosis (MS), while a lack of IL-10 production by B cells resulted in a severe chronic EAE. B cells can also suppress immunity via IL-35. Human B cells might similarly play inhibitory roles. In few patients with immune-mediated diseases B cell depletion therapy with Rituximab was associated with exacerbation of symptoms, or onset of new pathologies. Conversely, an opposite role of B cells as drivers of immunity was highlighted by the beneficial effect of Rituximab in some patients with rheumatoid arthritis or MS. Clinical improvement often precedes reduction in autoantibody levels in Rituximab treated patients, indicating that B cell-mediated pathogenesis is largely antibody-independent. A candidate factor for the deleterious effects of B cells in MS is IL-6. IL-6 secretion is a major mechanism of B cell-mediated pathogenesis in EAE, and B cells from MS patients produced more IL-6 than cells from healthy individuals. There is now an urgent need for the characterization of the phenotypes of the B cells producing IL-6, IL-10, and IL-35 in vivo at single cell and molecular levels. Markers for these cells might allow understanding the paradoxical effects of B cell-depletion therapy, and guide the development of novel agents depleting distinctively pro-inflammatory B cells, while sparing the remaining of the B cell compartment. Using advanced genetic models to identify and track cytokine-expressing cells, our project aims at characterizing B cells with pro- and anti-inflammatory functions in mice in vivo, to subsequently guide the identification of comparable markers in human.


year authors and title journal last update
List of publications.
2018 Simon Fillatreau
B cells and their cytokine activities implications in human diseases
published pages: 26-31, ISSN: 1521-6616, DOI: 10.1016/j.clim.2017.07.020
Clinical Immunology 186 2019-04-03
2018 Andreia C. Lino, Van Duc Dang, Vicky Lampropoulou, Anna Welle, Jara Joedicke, Jelka Pohar, Quentin Simon, Jessie Thalmensi, Aurelia Baures, Vinciane Flühler, Imme Sakwa, Ulrik Stervbo, Stefanie Ries, Luc Jouneau, Pierre Boudinot, Takeshi Tsubata, Takahiro Adachi, Andreas Hutloff, Thomas Dörner, Ursula Zimber-Strobl, Alex F. de Vos, Katja Dahlke, Gunnar Loh, Sarantis Korniotis, Christian Goosmann, Jean-Claude Weill, Claude-Agnès Reynaud, Stefan H.E. Kaufmann, Jörn Walter, Simon Fillatreau
LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells
published pages: 120-133.e9, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2018.06.007
Immunity 49/1 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREG-LAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREG-LAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DINAMIX (2019)

Real-time diffusion NMR analysis of mixtures

Read More  

AdjustNet (2020)

Self-Adjusting Networks

Read More  

CONTROL (2019)

Laser control over crystal nucleation

Read More